Sulfasalazine
- Generic Name
- Sulfasalazine
- Brand Names
- Azulfidine, Salazopyrin, Salazopyrin En-tabs
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14N4O5S
- CAS Number
- 599-79-1
- Unique Ingredient Identifier
- 3XC8GUZ6CB
- Background
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA). Metabolized by intestinal bacteria, sulfasalazine is broken down into mesalazine and sulfapyridine, 2 compounds that carry ...
- Indication
In the US, sulfasalazine is indicated to treat mild to moderate ulcerative colitis and to prolong the remission period between acute attacks of ulcerative colitis. Sulfasalazine is also indicated as an adjunct therapy in severe ulcerative colitis.For the delayed-release tablet formulation, sulfasalazine is also indicated to treat rheumatoid arthritis in pedi...
- Associated Conditions
- Crohn's Disease (CD), Distal Ulcerative Colitis, Mild to Moderate Ulcerative Colitis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Proctitis, Rheumatoid Arthritis, Severe Ulcerative Colitis, Ulcerative Colitis in Remission
- Associated Therapies
- -
Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT04205357
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT04077957
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 10
- Registration Number
- NCT03847311
- Locations
- 🇺🇸
Banner University Medical Center North Campus, Tucson, Arizona, United States
🇺🇸Banner University Medical Center South, Tucson, Arizona, United States
Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 106
- Registration Number
- NCT03813771
- Locations
- 🇬🇧
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT03801733
- Locations
- 🇨🇦
InVentiv Health Clinique Inc., Québec City, Quebec, Canada
Psoriatic Oligoarthritis Intervention With Symptomatic thErapy
- Conditions
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 1
- Registration Number
- NCT03797872
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 315
- Registration Number
- NCT03739853
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom
Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- St. James's Hospital, Ireland
- Target Recruit Count
- 40
- Registration Number
- NCT03734627
- Locations
- 🇮🇪
Department of Surgery, St. James's Hospital, Dublin, Ireland
🇮🇪Wellcome Trust-Health Research Board Clinical Research Facility, St. James's Hospital, Dublin, Ireland
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
- Conditions
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03561584
- Locations
- 🇺🇸
Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT03449758
- Locations
- 🇫🇷
Investigational Site Number 250014, Caen, France
🇫🇷Investigational Site Number 250006, Besancon, France
🇫🇷Investigational Site Number 250016, Bordeaux, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.